|
||
Article |
Cell adaptive response to extracellular matrix density is controlled by ICAP-1–dependent β1-integrin affinity
Correspondence to Corinne Albiges-Rizo: corinne.albiges-rizo{at}ujf-grenoble.fr
Cell migration is an integrated process requiring the continuous coordinated assembly and disassembly of adhesion structures. How cells orchestrate adhesion turnover is only partially understood. We provide evidence for a novel mechanistic insight into focal adhesion (FA) dynamics by demonstrating that integrin cytoplasmic domain–associated protein 1 (ICAP-1) slows down FA assembly. Live cell imaging, which was performed in both Icap-1–deficient mouse embryonic fibroblasts and cells expressing active β1 integrin, shows that the integrin high affinity state favored by talin is antagonistically controlled by ICAP-1. This affinity switch results in modulation in the speed of FA assembly and, consequently, of cell spreading and migration. Unexpectedly, the ICAP-1–dependent decrease in integrin affinity allows cell sensing of matrix surface density, suggesting that integrin conformational changes are important in mechanotransduction. Our results clarify the function of ICAP-1 in cell adhesion and highlight the central role it plays in the cell's integrated response to the extracellular microenvironment.
| Introduction |
|---|
|
|
|---|
and β subunits, leading to integrin activation (Luo et al., 2004; Vinogradova et al., 2004). Evidence suggests that the binding of a complex including talin, Rap1-GTP–interacting adaptor molecule, Rap1, and vasodilator-stimulated phosphoprotein (VASP) to the integrin cytoplasmic tail is a common final step in integrin activation (Han et al., 2006). Among integrin partners, integrin cytoplasmic domain–associated protein 1 (ICAP-1) encompassing a phosphotyrosine-binding domain interacts specifically with the cytoplasmic tail of β1 integrin at the membrane-distal NPXY motif. The increase of β1 integrin–dependent cell motility on fibronectin (FN) upon ICAP-1 overexpression (Chang et al., 1997, 2002; Zhang and Hemler, 1999) and cell rounding up after overexpression of a phosphomimetic mutant of ICAP-1 at the CaMKII site (Bouvard and Block, 1998) suggest that ICAP-1 might regulate β1-integrin function. Moreover, talin and ICAP-1 compete in vitro for integrin binding, and high ICAP-1 concentrations disrupt FA (Bouvard et al., 2003). ICAP-1 and β1 integrin are colocalized at the leading edges of cells during the early stages of spreading (Fournier et al., 2002). This facet of ICAP-1 in FA dynamics, which is obviously regulatory and transitory, prompted us to determine in more detail the role played by ICAP-1 in adhesion site dynamics.
In this study, we show that Icap-1–deficient mouse embryonic fibroblasts (MEFs) display defects in cellular spreading and migration correlating with the redistribution of FA, a modification in FA dynamics, and an increase in integrin affinity. These defects could be mimicked by increasing either integrin affinity or the surface density of the underlying matrix. By modulating integrin affinity, ICAP-1 allows the cell to adapt its adhesion strength and rate of migration to changes in the matrix surface density. These data point not only to the existence of specific molecules involved in FA assembly or disassembly signaling pathways but also to the control of FA assembly and matrix sensing through the fine-tuning of integrin affinity.
| Results |
|---|
|
|
|---|
|
|
ICAP-1 slows down the talin recruitment into FAs
The fact that Icap-1–null cells migrated and spread at lower matrix densities might reflect defects in adhesion dynamics. If ICAP-1 was involved in FA dynamics, differences are expected in the exchange or recruitment rate of some FA components between Icap-1–null cells and WT cells. To address this point, measurements of FRAP experiments were made using EGFP-fused vinculin or talin (Fig. 3).
Single FA in the lamella was photobleached, and their fluorescence recovery was recorded. Recovery times (
) were calculated for both fusion proteins. Our results revealed that EGFP-vinculin recruitment was four times faster than EGFP-talin in WT MEF cells spread on FN (Fig. 3 A). However, no difference between WT and Icap-1–deficient MEFs was observed in the incorporation speed of EGFP-vinculin into FAs, demonstrating that vinculin recruitment is ICAP-1 independent. Conversely, the recovery half-time associated with EGFP-talin was significantly lower in Icap-1–deficient MEFs, suggesting a faster recruitment of EGFP-talin in cells lacking ICAP-1. This conclusion is in line with the proposed competitive binding of ICAP-1 and talin for the β1-integrin cytoplasmic domain (Bouvard et al., 2003). FRAP experiments were also performed in cells spread on β3-integrin preferential substrate, such as VN to compare talin and vinculin recruitment in case of Icap-1 deficiency (Fig. 3 B). As expected, no significant change in talin recruitment was observed in both cells spread on VN. Our results demonstrate that the function of ICAP-1 is dependent on adhesion on specific substrate.
|
|
|
5β1-integrin affinity in osteoblasts issuing from Icap-1–null mice (Bouvard et al., 2007) and also suggests that this integrin affinity increase is cell type independent. To correlate the increase in β1-integrin affinity to the adhesive defect observed in Icap-1–null cells, integrins were chemically activated in WT cells to mimic the Icap-1–null phenotype (Fig. 6, B and C; and Fig. S4, available at http://www.jcb.org/cgi/content/full/jcb.200707142/DC1). Mn2+ treatment of both WT and rescued cell types shifted the spreading curve toward lower FN or CL surface densities, whereas it had no effect on Mn2+-treated Icap-1–null cells because their integrins are already in a high affinity state (Figs. 6 B and S4, A and B). These results were also confirmed with 9EG7 mAb, which is able to both recognize an activated β1 integrin–specific epitope and maintain it in its high affinity conformation (Figs. 6 C and S4 C). Thus, it was tempting to speculate that β1-integrin affinity could also control FA assembly. To test this hypothesis, we generated the activated β1-integrin mutant D759A with a disrupted salt bridge between
and β subunits (Hughes et al., 1996; Sakai et al., 1998; Partridge et al., 2005) and expressed it in β1 integrin–deficient GD25 cells. First, we confirmed that GD25/β1D759A cells displayed a higher affinity for the FNIII7-10 fragment than GD25/β1WT cells (Fig. 7 A).
At moderate FN surface densities, FAs were centrally distributed in GD25/β1D759A cells, whereas they were located on the periphery in control cells (Fig. 7 B). Both adhesive and migratory curves displayed a shift toward the lower matrix densities in mutant cells (Fig. 7 C). The coating concentration of FN giving the highest migration speed was approximately five times lower for GD25/β1D759A cells. Mn2+ treatment of GD25/β1WT integrin cells induced a shift in the spreading curve and mimicked the adhesive behavior of GD25/β1D759A and Icap-1–null cells. Finally, GD25/β1D759A cells displayed a faster rate of FA assembly, which is associated with a shorter lifetime, without any significant modification in the duration of the steady state or the disassembly rate (Fig. 7 D). Altogether, these results suggest that the adhesive defect in Icap-1–null cells was the result of the presence of β1 integrin in its active state and further implicate β1-integrin activation in the regulation of FA assembly.
|
|
|
| Discussion |
|---|
|
|
|---|
Our present work provides an array of convergent clues in support of a critical role for ICAP-1 in the control of FA turnover. Indeed, the faster assembly rate of FA in the lamella of Icap-1–null cells accelerates the maturation state of the adhesion and is associated with a slightly shorter steady state, resulting in a reduced lifetime. However, as the rate of FA disassembly is not modified by the lack of ICAP-1, this strongly suggests that disassembly is triggered by an ICAP-1–independent signaling pathway. Although some proteins such as paxillin and FAK are involved in FA disassembly (Webb et al., 2004; Schober et al., 2007; Zaidel-Bar et al., 2007), to date, ICAP-1 is the only regulatory molecule shown so far to negatively control the assembly phase. The specific interaction of ICAP-1 with the β1 integrins (Chang et al., 1997) combined with the change in the adhesion properties of Icap-1–null cells, depending on the integrin-engaging substrates, indicate that the observed modification in FA dynamics in these cells probably involves the participation of β1 integrins.
Modification in the dynamics of β1 integrin–containing FAs in Icap-1–null cells is also revealed by the faster recruitment of EGFP-talin into FAs observed by FRAP studies. This observation in living cells fits with in vitro talin–ICAP-1 competition assays as well as with the FA disruption and cell rounding up occurring after ICAP-1 overexpression. Although FRAP experiment could not definitively measure the increase of the on-rate of talin into FA, these results support the idea that ICAP-1 competes with talin for binding to the β1 cytosolic tail (Bouvard and Block, 1998; Bouvard et al., 2003). We propose that ICAP-1 can delay the talin–integrin interaction necessary for integrin activation and clustering (Giannone et al., 2003; Calderwood, 2004; Cluzel et al., 2005). This also suggests that by modulating talin–integrin interaction, ICAP-1 could limit the incorporation of β1 integrins into FAs, resulting in a modification in FA dynamics. However, we cannot exclude that the faster recruitment of talin into FA in Icap-1–null cells could be correlated with increased FAK or Src signaling in the β1 integrin–enriched FA. This could also indicate an alteration in the affinity of talin for β1 integrin, resulting in the overall instability of FAs and their faster FA turnover. Our FACS analysis of fluorescent FNIII7-10 binding on cells in suspension show that the loss of ICAP-1 increases the affinity of integrin for the ligand, although not as much as is achieved by incubation with either with Mn2+ or 9EG7 antibody. This favors the hypothesis whereby ICAP-1 limits a state of preactivation necessary for the following steps of activation. Without ICAP-1, this limitation is switched off, which, in turn, accelerates cellular mechanisms such as spreading or migration. Interestingly, when cells spread or migrate, any means of integrin activation (D/A, ICAP-1 loss, or chemical treatment) results in the same phenotype. This fits with our observation that D/A and Icap-1–null cells share the same phenotype but also suggests that either a threshold in integrin activation exists or that integrin activation is tightly controlled in space and time by a multistep process, implying different integrin states from preactivation to full activation of integrin as already suggested (Clark et al., 2005). Moreover, FA distribution in the cell central region is cell type specific because β1 integrin–deficient osteoblasts infected with D759A human β1 integrin display more FA in the cell central region compared with GD25/β1D759A cells (unpublished data).
Although the control of the β1-integrin high affinity state has been well characterized and is largely attributed to the interaction with talin (Calderwood, 2004), the mechanisms restricting β1 integrin in a low affinity state are still unknown. Here, we show that ICAP-1 loss results in increased β1-integrin affinity in MEFs, as previously described for osteoblasts (Bouvard et al., 2007). Importantly, this increase of β1-integrin affinity in Icap-1–null cells results in faster FA turnover and in the inability of the cells to adapt their adhesive properties. This abnormal switch of β1 integrins toward the high affinity state results in maximal cell spreading and migratory response on a coating of minimal substrate density even though no migration defect has been noticed in Icap-1–null mice during embryogenesis. Nevertheless, we can neither exclude the presence of a more subtle defect nor exclude the possibility of a migration defect in Icap-1–null mice during repair or pathogenesis. Mice expressing a D759A mutation in β1 locus have been recently described (Czuchra et al., 2006). In contrast to Icap-1–null mice, those animals do not display significant abnormalities (Czuchra et al., 2006). However, although talin binding onto β1 integrin is required for its full activation in both mutants, the absence of ICAP-1 expression would favor talin binding, whereas ICAP-1 would still limit this step in the case of the D/A mutation. It is also important to note the discrepancy of adhesive phenotype between keratinocytes isolated from D/A mice (Czuchra et al., 2006) and Icap-1–null cells, which could arise from the different integrin repertoires between mesenchymal cells (MEFs or osteoblasts) and epithelial cells (keratinocytes). Furthermore, Icap-1–deficient mice also suffer from a strong osteoblast proliferation defect that could be integrin independent (Bouvard et al., 2007).
However, our results indicate that a balance between low and high affinity integrin states is necessary for proper sensing of the ECM density, which, in turn, has important consequences for migration and spreading. Cell adhesion is continually adapted in response to changes in substrate concentration and structure or to mechanical cues at the cell–matrix interface. Distinct FA and actin cytoskeleton organization and dynamics have been shown to depend on the strength of cell adhesion (Gupton and Waterman-Storer, 2006). Our data provide new insight by adding integrin affinity regulation to the molecular mechanisms controlling these different processes. Change in adhesive properties can be predicted on the basis of the redistribution of FA. In our study, the hallmark of increased integrin affinity, corresponding to the signature of cellular adaptation to a particular matrix environment, is the redistribution of FA throughout the ventral cell surface accompanied by an expansion in their areas. These central FAs do not display the characteristics of fibrillar adhesions and are not correlated with an increased capacity to deposit FN matrix (unpublished data). Cells lacking ICAP-1 are much less capable of sensing different matrix densities; consequently, maximal response is elicited by a minimum matrix density environment. Cell adaptive response and stem cell lineage specification may arise from substrate stiffness (Discher et al., 2005; Paszek et al., 2005; Engler et al., 2006). This inability to feel their environment has important consequences for in vivo function. Indeed, Icap-1–null mice suffer from an important osteogenesis dysfunction resulting from reduced proliferation and delayed differentiation of the osteoblast population. Icap-1–deficient preosteoblasts present a condensation defect that further limits the number of progenitors that will finally differentiate into mature osteoblasts (Bouvard et al., 2007). This cell compaction defect could be a consequence of the cells' inability to sense the matrix density or organization. The pronounced phenotype in osteoblasts may be caused by their extraordinary need for mechanosensitivity to mediate bone formation and remodeling along with the necessity of being aware of the inherent variability in cellular response to differences in matrix density or stiffness (Leucht et al., 2007). Although it is clear from previous work that β1-integrin expression is crucial for development and tissue homeostasis, we clearly establish that a switch between high and low affinity integrin states is required to drive an integrated cell response that is appropriate for the ECM environment. This is achieved by specific integrin regulators such as talin, ICAP-1, and possibly other proteins that are central to the control of FA dynamics during cell adhesion.
| Materials and methods |
|---|
|
|
|---|
Cell culture, transfection, retroviral infection, and plasmid construction
Primary MEFs were isolated from embryonic day 14.5 WT or Icap-1–deficient embryos using a standard procedure. Immortalized osteoblasts from Icap-1+/+ and Icap-1–null mice as well as Icap-1–null osteoblasts rescued with Icap-1 were generated as described previously (Bouvard et al., 2007). MEF, GD25, and osteoblast cells were cultured in DME supplemented with 10% FCS (Invitrogen) and 100 U/ml penicillin/100 µg/ml streptomycin at 37°C in a 5% CO2-humidified chamber. Cells were transfected with the cDNA constructs using ExGen 500 (Euromedex). The expression vectors were pEGFP-C1-vinculin, pEGFP-C1-paxillin (provided by K. Nakamura, Osaka Bioscience Institute, Osaka, Japan), pEGFP-C1-talin (provided by A. Huttenlocher, University of Wisconsin, Madison, WI), pBabe β1-WT, pBabe β1(D759A), pBabe-EGFP-VASP (provided by F. Gertler, Massachusetts Institute of Technology, Cambridge, MA), and pCLMFG-IRES–ICAP-1. Retroviral plasmid encoding human WT β1 integrin or the D759A mutant was performed using standard protocols. In brief, a HindIII subclone fragment was used for PCR-mediated mutagenesis using the QuikChange Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's instructions and was reinserted into the full sequence to swap the WT sequence using HindIII digest. Human WT or mutant β1 integrin was then inserted into the pBabe retroviral vector using EcoRI and XhoI sites. All sequences were verified by DNA sequencing (Genome Express). β1 Integrin–null GD25 cells were transfected with pBabe containing either WT or D759A β1 integrin and were selected in the presence of 1 µg/ml puromycin. For retroviral infection, cells were incubated for 24 h at 37°C with either pBabe-EGFP-VASP, pCLMFG-Ires–ICAP-1, or pCLMFG-EGFP-zyxin retrovirus containing supernant in 10% FCS-DME and 4 µg/ml Polybrene (Sigma Aldrich) as previously described (Bouvard et al., 2007).
Western blotting
MEF cells were lysed in radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors (Roche). Proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes. Immunological detection was achieved with appropriate HRP-conjugated secondary antibody. Peroxidase activity was visualized by chemiluminescence (ECL; GE Healthcare).
Immunofluorescence staining of cells
Cells were fixed with 4% PFA, permeabilized with 0.2% Triton X-100, and incubated with appropriate primary antibodies. After rinsing, coverslips were incubated with an appropriate AlexaFluor-conjugated secondary antibody. The cells were mounted in Mowiol/DAPI solution and imaged on an inverted confocal microscope (LSM510; Carl Zeiss, Inc.).
Spreading assays
Cell adhesion assays were performed using 35-mm-diameter hydrophobic dishes coated with various concentrations of matrix. Cells were trypsinized, treated with 1 mg/ml trypsin inhibitor (Sigma-Aldrich), and incubated in serum-free DME/5% BSA for 1 h at 37°C. Cells were plated at a density of 2 x 104 cells per dish in 2 ml DME containing FN-free 10% FCS. After 1.5 h of incubation at 37°C, cells were photographed and scored as round or flattened using three fields for each experimental condition. When Mn2+ was supplemented, cells were treated for 10 min at 37°C in suspension with 0.5 mM MnCl2 in DME containing FN-free FCS before seeding. Alternatively, cells were treated with 10 µg/ml mAb(9EG7) for 30 min at 4°C in DME containing FN-free FCS.
Migration assays
For transwell assays, polycarbonate membranes (8-µm pores; BD Biosciences) were coated on both sides overnight with various concentrations of matrix. After washing with PBS, chambers were transferred in 24-well plates containing either serum-free DME or DME plus FN-free serum. Serum-starved cells were trypsinized and treated with trypsin inhibitor. 15 x 103 cells were seeded in the upper chamber in 1 ml of serum-free DME and allowed to migrate to the underside of the membrane for 8 h. Cell migration was stopped by fixing and staining with Coomassie blue. Excess dye was removed with isopropanol/acetic acid. After removal of the nonmigrating cells in the upper well, migrating cells were photographed at 10x magnification and counted using three randomly chosen microscopic fields.
Time-lapse video microscopy was performed using chambered coverglass (LabTekII; Thermo Fisher Scientific) coated with various concentrations of FN. Trypsinized cells were treated with trypsin inhibitor and incubated in 5% BSA for 1 h at 37°C. Cells were then plated in LabTekII chambers containing DME supplemented with FN-free serum. After 1 h of spreading, cells were observed at 10x magnification using an inverted microscope (Axiovert 100; Carl Zeiss, Inc.) equipped with an on-stage incubator (XL-3; PeCon). Six to eight isolated fields were arbitrary chosen, and phase-contrast images were taken at 4-min intervals over a period of 5 h. Cells were tracked using the position of centroids with MetaMorph software (Roper Scientific).
FNIII7-10 binding assay and flow cytometry analysis
MEF or GD25 cells were harvested after trypsin treatment, washed in the presence of trypsin inhibitor, and incubated (3 x 105 cells per sample) with 3 µM FITC-coupled FNIII7-10 fragment (provided by F. Coussin, Unité Mixte de Recherche 5017, Bordeaux, France) in Tyrode buffer supplemented with 1% BSA for 1 h in the presence or absence of 5 mM EDTA and 5 mM EGTA. After washing with Tyrode/BSA, the cells were fixed and subjected to flow cytometry analysis using a FACScan flow cytometer (BD Biosciences). The collected data were analyzed using CellQuest software (BD Biosciences). In parallel, MEF or GD25 cells were analyzed by FACS for cell surface β1- or β3-integrin expression using either the MB1.2 rat mAb (against mouse β1 integrin), the 4B7R mouse mAb (against human β1 integrin), or the anti–mouse β3-integrin rat mAb (against mouse β3 integrin). The activation index of β1 integrin was estimated as previously described (Bouvard et al., 2007). Each specific MFI was calculated by subtracting the background obtained with FnIII7-10 fragment incubation in the presence of EDTA or without the primary antibody in the case of the integrin labeling. For instance, for the estimation of human β1-integrin activation (GD25 cells), activation index = ([MFI FnIII7-10]–[MFI FnIII7-10 + EDTA])/([MFI 4B7R]–[MFI 4B7R control]).
Nocodazole assay
Cells were serum starved for 48 h in DME containing 0.5% fatty acid–free BSA and were treated with 10 µM nocodazole for 4 h to completely depolymerize microtubules. The drug was washed out with serum-free DME medium containing 0.5% fatty acid–free BSA, and microtubules were allowed to repolymerize for different time intervals. Cells were fixed and permeabilized before processing for immunofluorescence.
Quantification of FA area and intensity
Fixed and stained cells were imaged on a nonlinear optics LSM510 inverted confocal and biphoton laser-scanning microscope equipped with a 63x NA 1.4 oil-immersion plan Apochromat objective (Carl Zeiss, Inc.). The fluorescence of AlexaFluor488 and 546 was excited with 488- or 543-nm wavelengths and detected in confocal mode. AlexaFluor350 fluorescence was induced by two-photon absorption at 720 nm using the fs Ti-Sa laser (Tsunami; Spectra-Physics). Neither signal saturation nor significant photobleaching was induced during image acquisition in either detection channel.
The images were manually thresholded, and FAs were automatically selected using MetaMorph software within the predefined regions of the cell. The number and areas of FAs and the MFIs of β1, β3 integrin, vinculin, and paxillin in FAs were quantified.
Time-lapse video microscopy and quantification of FA dynamics
Time-lapse recordings were assessed either on MEF cells expressing EGFP-paxillin, EGFP-VASP, or EGFP-vinculin and on GD25 cells expressing EGFP-zyxin. Cells were cultured in FN-free FCS-DME on LabTekII chambers previously coated with the indicated concentrations of matrix. Living cells were maintained at 37°C in a 5% CO2 atmosphere under an inverted microscope (Axiovert 200M; Carl Zeiss, Inc.) equipped with a motorized stage, cooled CCD camera (CoolSNAP HQ2; Roper Scientific), and a live cell imaging plan Apochromat 63x NA 1.2 water immersion objective (Carl Zeiss, Inc.). To minimize the possible photobleaching and light-induced cell damage, the excitation light of a 100-W Hg lamp was reduced to 30% with a FluoArc system (Carl Zeiss, Inc.) and additionally attenuated with a filter (ND75; Carl Zeiss, Inc.). 15 isolated cells were randomly chosen for each experimental condition, and 10–15 control WT cells were recorded simultaneously. Images were acquired, looping all stage positions at 4-min intervals over 6 h. The turnover of FAs located at the cell front was quantified using MetaMorph software. In brief, the adhesion area was outlined on the raw images during steady state, and then adhesion was manually followed from its nucleation. The MFI in the same area was measured, subtracting the background value. Four parameters of adhesion turnover were determined: the total lifetime, the period of steady state, and the rates of assembly and disassembly.
FRAP
MEF cells transiently expressing EGFP-talin or EGFP-vinculin were cultured on LabTekII chambers (Thermo Fisher Scientific) previously coated with either 20 µg/ml FN or 5 µg/ml VN. FRAP experiments were performed with an LSM510 confocal microscope equipped with the on-stage incubator. One individual FA per cell located at the leading edge was processed by FRAP. EGFP fluorescence in the adhesion area was eliminated by 100 bleach cycles at 100% intensity of the 488-nm argon laser. The fluorescence recovery was then sampled with low laser power (2–3%) each minute for 15–20 min. The recovery curves were obtained using MetaMorph software by measuring the MFI in the bleached region and correcting it to the overall image photobleaching. The corrected curve was adjusted with Kaleidagraph software (SynergySoftware) using the monoexponential fit. The characteristic recovery time,
, was the mean of at least 20 individual FAs.
Online supplemental material
Fig. S1 shows the distribution of β3 integrin containing FAs and the expression of adhesion proteins in WT and Icap-1–null MEF cells. Fig. S2 shows the spreading and migration on increased FN matrix densities of WT, Icap-1–null, and rescued Icap-1–null MEF cells. Fig. S3 illustrates the adhesive behavior (cell migration, spreading, and FA dynamics) of WT and Icap-1–null MEF cells spread on VN, a β3 integrin–specific matrix. Fig. S4 shows that β1-integrin activation in WT MEFs and rescued Icap-1–null osteoblasts induces a similar spreading to Icap-1–null cells. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200707142/DC1.
| Acknowledgments |
|---|
This work was supported by a grant from the Ligue Nationale Contre le Cancer, the Association de Recherche pour le Cancer, Areca, the Groupement des Entreprises Françaises Monegasques dans la Lutte contre le Cancer, and the Région Rhône-Alpes. A. Millon-Frémillon was supported by a fellowship from the Ministère de l'Education Nationale de la Recherche et de la Technologie.
Submitted: 20 July 2007
Accepted: 26 December 2007
| References |
|---|
|
|
|---|
Albiges-Rizo, C., P. Frachet, and M.R. Block. 1995. Down regulation of talin alters cell adhesion and the processing of the alpha 5 beta 1 integrin. J. Cell Sci. 108:3317–3329.[Abstract]
Bennett, J.S. 2005. Structure and function of the platelet integrin alphaIIbbeta3. J. Clin. Invest. 115:3363–3369.[CrossRef][Medline]
Bershadsky, A.D., N.Q. Balaban, and B. Geiger. 2003. Adhesion-dependent cell mechanosensitivity. Annu. Rev. Cell Dev. Biol. 19:677–695.[CrossRef][Medline]
Bhatt, A., I. Kaverina, C. Otey, and A. Huttenlocher. 2002. Regulation of focal complex composition and disassembly by the calcium-dependent protease calpain. J. Cell Sci. 115:3415–3425.
Bouvard, D., and M.R. Block. 1998. Calcium/calmodulin-dependent protein kinase II controls integrin alpha5beta1-mediated cell adhesion through the integrin cytoplasmic domain associated protein-1alpha. Biochem. Biophys. Res. Commun. 252:46–50.[CrossRef][Medline]
Bouvard, D., L. Vignoud, S. Dupe-Manet, N. Abed, H.N. Fournier, C. Vincent-Monegat, S.F. Retta, R. Fassler, and M.R. Block. 2003. Disruption of focal adhesions by integrin cytoplasmic domain-associated protein-1 alpha. J. Biol. Chem. 278:6567–6574.
Bouvard, D., A. Aszodi, G. Kostka, M.R. Block, C. Albiges-Rizo, and R. Fassler. 2007. Defective osteoblast function in ICAP-1-deficient mice. Development. 134:2615–2625.
Calderwood, D.A. 2004. Integrin activation. J. Cell Sci. 117:657–666.
Calderwood, D.A., B. Yan, J.M. de Pereda, B.G. Alvarez, Y. Fujioka, R.C. Liddington, and M.H. Ginsberg. 2002. The phosphotyrosine binding-like domain of talin activates integrins. J. Biol. Chem. 277:21749–21758.
Chang, D.D., C. Wong, H. Smith, and J. Liu. 1997. ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of β1 integrin. J. Cell Biol. 138:1149–1157.
Chang, D.D., B.Q. Hoang, J. Liu, and T.A. Springer. 2002. Molecular basis for interaction between Icap1 alpha PTB domain and beta 1 integrin. J. Biol. Chem. 277:8140–8145.
Chen, C.S., J. Tan, and J. Tien. 2004. Mechanotransduction at cell-matrix and cell-cell contacts. Annu. Rev. Biomed. Eng. 6:275–302.[CrossRef][Medline]
Clark, K., R. Pankov, M.A. Travis, J.A. Askari, A.P. Mould, S.E. Craig, P. Newham, K.M. Yamada, and M.J. Humphries. 2005. A specific alpha5beta1-integrin conformation promotes directional integrin translocation and fibronectin matrix formation. J. Cell Sci. 118:291–300.
Cluzel, C., F. Saltel, J. Lussi, F. Paulhe, B.A. Imhof, and B. Wehrle-Haller. 2005. The mechanisms and dynamics of
vβ3 integrin clustering in living cells. J. Cell Biol. 171:383–392.
Czuchra, A., H. Meyer, K.R. Legate, C. Brakebusch, and R. Fassler. 2006. Genetic analysis of β1 integrin "activation motifs" in mice. J. Cell Biol. 174:889–899.
Discher, D.E., P. Janmey, and Y.L. Wang. 2005. Tissue cells feel and respond to the stiffness of their substrate. Science. 310:1139–1143.
Engler, A.J., S. Sen, H.L. Sweeney, and D.E. Discher. 2006. Matrix elasticity directs stem cell lineage specification. Cell. 126:677–689.[CrossRef][Medline]
Ezratty, E.J., M.A. Partridge, and G.G. Gundersen. 2005. Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase. Nat. Cell Biol. 7:581–590.[CrossRef][Medline]
Fournier, H.N., S. Dupe-Manet, D. Bouvard, M.L. Lacombe, C. Marie, M.R. Block, and C. Albiges-Rizo. 2002. Integrin cytoplasmic domain-associated protein 1alpha (ICAP-1alpha) interacts directly with the metastasis suppressor nm23-H2, and both proteins are targeted to newly formed cell adhesion sites upon integrin engagement. J. Biol. Chem. 277:20895–20902.
Franco, S.J., M.A. Rodgers, B.J. Perrin, J. Han, D.A. Bennin, D.R. Critchley, and A. Huttenlocher. 2004. Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat. Cell Biol. 6:977–983.[CrossRef][Medline]
Giannone, G., G. Jiang, D.H. Sutton, D.R. Critchley, and M.P. Sheetz. 2003. Talin1 is critical for force-dependent reinforcement of initial integrin-cytoskeleton bonds but not tyrosine kinase activation. J. Cell Biol. 163:409–419.
Ginsberg, M.H., A. Partridge, and S.J. Shattil. 2005. Integrin regulation. Curr. Opin. Cell Biol. 17:509–516.[CrossRef][Medline]
Gupton, S.L., and C.M. Waterman-Storer. 2006. Spatiotemporal feedback between actomyosin and focal-adhesion systems optimizes rapid cell migration. Cell. 125:1361–1374.[CrossRef][Medline]
Han, J., C.J. Lim, N. Watanabe, A. Soriani, B. Ratnikov, D.A. Calderwood, W. Puzon-McLaughlin, E.M. Lafuente, V.A. Boussiotis, S.J. Shattil, and M.H. Ginsberg. 2006. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr. Biol. 16:1796–1806.[CrossRef][Medline]
Hughes, P.E., F. Diaz-Gonzalez, L. Leong, C. Wu, J.A. McDonald, S.J. Shattil, and M.H. Ginsberg. 1996. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J. Biol. Chem. 271:6571–6574.
Hynes, R.O. 2002. Integrins: bidirectional, allosteric signaling machines. Cell. 110:673–687.[CrossRef][Medline]
Ingber, D.E. 2003. Mechanosensation through integrins: cells act locally but think globally. Proc. Natl. Acad. Sci. USA. 100:1472–1474.
Jiang, G., G. Giannone, D.R. Critchley, E. Fukumoto, and M.P. Sheetz. 2003. Two-piconewton slip bond between fibronectin and the cytoskeleton depends on talin. Nature. 424:334–337.[CrossRef][Medline]
Kaverina, I., O. Krylyshkina, and J.V. Small. 1999. Microtubule targeting of substrate contacts promotes their relaxation and dissociation. J. Cell Biol. 146:1033–1044.
Leucht, P., J.B. Kim, J.A. Currey, J. Brunski, and J.A. Helms. 2007. FAK-mediated mechanotransduction in skeletal regeneration. PLoS ONE. 2:e390.[CrossRef]
Liddington, R.C., and M.H. Ginsberg. 2002. Integrin activation takes shape. J. Cell Biol. 158:833–839.
Luo, B.H., T.A. Springer, and J. Takagi. 2004. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol. 2:e153.[CrossRef][Medline]
Martel, V., C. Racaud-Sultan, S. Dupe, C. Marie, F. Paulhe, A. Galmiche, M.R. Block, and C. Albiges-Rizo. 2001. Conformation, localization, and integrin binding of talin depend on its interaction with phosphoinositides. J. Biol. Chem. 276:21217–21227.
Partridge, A.W., S. Liu, S. Kim, J.U. Bowie, and M.H. Ginsberg. 2005. Transmembrane domain helix packing stabilizes integrin alphaIIbbeta3 in the low affinity state. J. Biol. Chem. 280:7294–7300.
Paszek, M.J., N. Zahir, K.R. Johnson, J.N. Lakins, G.I. Rozenberg, A. Gefen, C.A. Reinhart-King, S.S. Margulies, M. Dembo, D. Boettiger, et al. 2005. Tensional homeostasis and the malignant phenotype. Cancer Cell. 8:241–254.[CrossRef][Medline]
Priddle, H., L. Hemmings, S. Monkley, A. Woods, B. Patel, D. Sutton, G.A. Dunn, D. Zicha, and D.R. Critchley. 1998. Disruption of the talin gene compromises focal adhesion assembly in undifferentiated but not differentiated embryonic stem cells. J. Cell Biol. 142:1121–1133.
Raftopoulou, M., and A. Hall. 2004. Cell migration: Rho GTPases lead the way. Dev. Biol. 265:23–32.[CrossRef][Medline]
Sakai, T., Q. Zhang, R. Fassler, and D.F. Mosher. 1998. Modulation of β1A integrin functions by tyrosine residues in the β1 cytoplasmic domain. J. Cell Biol. 141:527–538.
Schober, M., S. Raghavan, M. Nikolova, L. Polak, H.A. Pasolli, H.E. Beggs, L.F. Reichardt, and E. Fuchs. 2007. Focal adhesion kinase modulates tension signaling to control actin and focal adhesion dynamics. J. Cell Biol. 176:667–680.
Tadokoro, S., S.J. Shattil, K. Eto, V. Tai, R.C. Liddington, J.M. de Pereda, M.H. Ginsberg, and D.A. Calderwood. 2003. Talin binding to integrin beta tails: a final common step in integrin activation. Science. 302:103–106.
Takagi, J., and T.A. Springer. 2002. Integrin activation and structural rearrangement. Immunol. Rev. 186:141–163.[CrossRef][Medline]
Vinogradova, O., J. Vaynberg, X. Kong, T.A. Haas, E.F. Plow, and J. Qin. 2004. Membrane-mediated structural transitions at the cytoplasmic face during integrin activation. Proc. Natl. Acad. Sci. USA. 101:4094–4099.
Webb, D.J., K. Donais, L.A. Whitmore, S.M. Thomas, C.E. Turner, J.T. Parsons, and A.F. Horwitz. 2004. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat. Cell Biol. 6:154–161.[CrossRef][Medline]
Zaidel-Bar, R., R. Milo, Z. Kam, and B. Geiger. 2007. A paxillin tyrosine phosphorylation switch regulates the assembly and form of cell-matrix adhesions. J. Cell Sci. 120:137–148.
Zhang, X.A., and M.E. Hemler. 1999. Interaction of the integrin beta1 cytoplasmic domain with ICAP-1 protein. J. Biol. Chem. 274:11–19.
Related In this Issue article
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|